We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons Why Investors Should Consider Betting on Arvinas Stock
Read MoreHide Full Article
Key Takeaways
Arvinas' Veppanu became the first FDA-approved PROTAC protein degrader in May 2026.
The Veppanu deal offers $70 million upfront, up to $320 million in milestones and tiered royalties.
ARVN's pipeline spans lymphoma, Parkinson's disease and solid tumors, with data expected through 2027.
Arvinas (ARVN - Free Report) is a clinical-stage biotechnology company focused on developing innovative medicines using its proprietary PROteolysis TArgeting Chimera (PROTAC) protein degradation technology. The company’s product candidates, particularly those targeting hormone-driven breast cancer, and its broader pipeline provide potential long-term growth opportunities.
Veppanu’s Approval Validates Arvinas’ Technology
Veppanu (vepdegestrant), approved by the FDA in May 2026, is Arvinas’ first product. The approval marked an important milestone for the company, as Veppanu became the first FDA-approved PROTAC protein degrader. This achievement provides clinical validation for the company’s technology and demonstrates its ability to deliver medicines that remove disease-causing proteins.
The drug is approved to treat certain adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. Veppanu was developed in collaboration with Pfizer (PFE - Free Report) and the companies subsequently out-licensed the drug’s exclusive global development, manufacturing and commercialization rights to Rigel Pharmaceuticals (RIGL - Free Report) .
Under the May 2026 agreement, Arvinas and Pfizer are entitled to receive a $70 million upfront payment and are also eligible for an additional $15 million upon completion of transition activities. They may also receive up to $320 million in development, regulatory and commercial milestone payments, plus tiered royalties on net sales. This agreement allows Arvinas to earn collaboration revenue without directly managing global sales, although future payments will depend on the drug’s commercial success.
Year to date, ARVN shares have lost 37.1% against the industry’s 3.7% growth.
Image Source: Zacks Investment Research
Diversified Pipeline Remains a Key to ARVN’s Growth
Arvinas’ pipeline extends beyond Veppanu. The company is advancing several investigational drug candidates that could support its long-term growth. ARV-393, an oral BCL6 degrader, is being evaluated in a phase I study in patients with non-Hodgkin lymphoma. Early results have shown preliminary responses in B- and T-cell lymphomas, and the company is also studying the drug in combination with glofitamab in patients with diffuse large B-cell lymphoma. Arvinas plans to present additional clinical data in the second half of 2026 and in 2027.
ARV-102, an oral LRRK2 degrader, is being developed for neurological disorders, including Parkinson’s disease. The company plans to share additional biomarker data this month and continue discussions with global health authorities about potential clinical trials in progressive supranuclear palsy in 2027. Meanwhile, ARV-027, an oral androgen receptor degrader, has completed the single-dose cohorts of its phase I study in healthy volunteers and begun multiple-dose testing. Initial data on androgen receptor degradation in muscle are expected in the first half of 2027.
Arvinas is also developing ARV-6723, its first investigational immuno-oncology candidate, which targets the HPK1 protein to enhance immune-cell activity against cancer. Following encouraging preclinical findings, the company initiated a phase I study in patients with advanced solid tumors in September 2026. ARV-806, an oral KRAS G12D degrader, has completed enrollment in its phase I dose-escalation study, with initial monotherapy data expected later in 2026. The company is seeking a licensing partner for further clinical development of the candidate, including dose expansion and combination studies.
Over the past 60 days, estimates for ARVN’s 2026 bottom line have improved from a loss of 27 cents to earnings per share of 5 cents and 2027 estimates for loss per share have also improved from $3.44 to $3.37.
View the Zacks #1 Rank List
Image: Bigstock
Reasons Why Investors Should Consider Betting on Arvinas Stock
Key Takeaways
Arvinas (ARVN - Free Report) is a clinical-stage biotechnology company focused on developing innovative medicines using its proprietary PROteolysis TArgeting Chimera (PROTAC) protein degradation technology. The company’s product candidates, particularly those targeting hormone-driven breast cancer, and its broader pipeline provide potential long-term growth opportunities.
Veppanu’s Approval Validates Arvinas’ Technology
Veppanu (vepdegestrant), approved by the FDA in May 2026, is Arvinas’ first product. The approval marked an important milestone for the company, as Veppanu became the first FDA-approved PROTAC protein degrader. This achievement provides clinical validation for the company’s technology and demonstrates its ability to deliver medicines that remove disease-causing proteins.
The drug is approved to treat certain adults with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. Veppanu was developed in collaboration with Pfizer (PFE - Free Report) and the companies subsequently out-licensed the drug’s exclusive global development, manufacturing and commercialization rights to Rigel Pharmaceuticals (RIGL - Free Report) .
Under the May 2026 agreement, Arvinas and Pfizer are entitled to receive a $70 million upfront payment and are also eligible for an additional $15 million upon completion of transition activities. They may also receive up to $320 million in development, regulatory and commercial milestone payments, plus tiered royalties on net sales. This agreement allows Arvinas to earn collaboration revenue without directly managing global sales, although future payments will depend on the drug’s commercial success.
Year to date, ARVN shares have lost 37.1% against the industry’s 3.7% growth.
Image Source: Zacks Investment Research
Diversified Pipeline Remains a Key to ARVN’s Growth
Arvinas’ pipeline extends beyond Veppanu. The company is advancing several investigational drug candidates that could support its long-term growth. ARV-393, an oral BCL6 degrader, is being evaluated in a phase I study in patients with non-Hodgkin lymphoma. Early results have shown preliminary responses in B- and T-cell lymphomas, and the company is also studying the drug in combination with glofitamab in patients with diffuse large B-cell lymphoma. Arvinas plans to present additional clinical data in the second half of 2026 and in 2027.
ARV-102, an oral LRRK2 degrader, is being developed for neurological disorders, including Parkinson’s disease. The company plans to share additional biomarker data this month and continue discussions with global health authorities about potential clinical trials in progressive supranuclear palsy in 2027. Meanwhile, ARV-027, an oral androgen receptor degrader, has completed the single-dose cohorts of its phase I study in healthy volunteers and begun multiple-dose testing. Initial data on androgen receptor degradation in muscle are expected in the first half of 2027.
Arvinas is also developing ARV-6723, its first investigational immuno-oncology candidate, which targets the HPK1 protein to enhance immune-cell activity against cancer. Following encouraging preclinical findings, the company initiated a phase I study in patients with advanced solid tumors in September 2026. ARV-806, an oral KRAS G12D degrader, has completed enrollment in its phase I dose-escalation study, with initial monotherapy data expected later in 2026. The company is seeking a licensing partner for further clinical development of the candidate, including dose expansion and combination studies.
Arvinas, Inc. Price and Consensus
Arvinas, Inc. price-consensus-chart | Arvinas, Inc. Quote
ARVN's Zacks Rank & Estimates
Arvinas currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for ARVN’s 2026 bottom line have improved from a loss of 27 cents to earnings per share of 5 cents and 2027 estimates for loss per share have also improved from $3.44 to $3.37.